NCT04600362View on ClinicalTrials.gov

Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

September 1, 2025

Study Completion Date

January 31, 2027

Conditions
Nummular Eczema
Interventions
DRUG

Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Subcutaneous

Trial Locations (1)

81675

Klinikum re. Isar Dermatology, München

All Listed Sponsors
collaborator

University Hospital Munich

OTHER

lead

Technical University of Munich

OTHER